Why Jim Cramer Says Investors Should Watch DexCom (DXCM) Stock

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says DexCom (DXCM), a company that makes glucose monitoring systems, should be on investors' radars.

DexCom's devices, which do not require finger pricking, have a disruptive technology that caused the stock to soar. But at the end of February, when investors pulled away from cash flow positive stories and went to earnings per share stories, the stock plummeted. Another problem is the company has also added a lot of expenses because it is adding salespeople.

Cramer suggests following the stock because it provides an indication of when momentum stocks will come back to life. He expects the company to be cash flow positive in 2015 and could be earnings per share positive. Cramer says this stock is hated but if it gets love, then many other stocks will act well.

Must Watch: Jim Cramer on Why DexCom Could be a Good Portfolio Addition

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DXCM Chart

DXCM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Comcast, Lululemon, EQT and Other New Activist Investments

Comcast, Lululemon, EQT and Other New Activist Investments

The Case for the Bears: Cramer's 'Mad Money' Recap (Wed 10/4/17)

The Case for the Bears: Cramer's 'Mad Money' Recap (Wed 10/4/17)

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus